Article Text

PDF
Letter
Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features
  1. Michael Absoud1,
  2. Ming J Lim1,
  3. Richard Appleton2,
  4. Anu Jacob3,
  5. Joanna Kitley4,
  6. M Isabel Leite4,
  7. Michael G Pike5,
  8. Angela Vincent4,
  9. Evangeline Wassmer6,
  10. Patrick Waters4,
  11. Mark Woodhall4,
  12. Cheryl Hemingway7,
  13. Jacqueline Palace4
  1. 1 Department of Children's Neurosciences, Evelina Children's Hospital at Guy's & St Thomas’ NHS Foundation Trust, Kings Health Partners Academic Health Science Centre, London, UK
  2. 2 The Roald Dahl EEG Unit, Pediatric Neurosciences Foundation, Alder Hey Children's Hospital, Liverpool, UK
  3. 3 Department of Neurology, The Walton Centre for Neurology and Neurosurgery, Liverpool, North Lincolnshire, UK
  4. 4 Nuffield Department of Clinical Neurosciences, Oxford University Hospitals National Health Service Trust, University of Oxford, Oxford, UK
  5. 5 Department of Neurology, Oxford Children's Hospital, Oxford University Hospitals National Health Service Trust, Oxford, UK
  6. 6 Department of Neurology, Birmingham Children's Hospital, Birmingham, UK
  7. 7 Department of Neurology, Great Ormond Street Hospital for Children, London, UK
  1. Correspondence to Dr Michael Absoud, Department of Children's Neurosciences, Staircase D South Wing, Evelina Children's Hospital at Guy's & St Thomas’ NHS Foundation Trust, London SE1 7EH,UK; michael.absoud{at}gstt.nhs.uk

Abstract

Background Neuromyelitis Optica (NMO) is a severe and rare inflammatory condition, where relapses are predictive of disability.

Methods We describe a national paediatric NMO cohort's clinical, MRI, outcome, and prognostic features in relation to Aquaporin-4 antibody (AQP4-Ab) status, and compared to a non NMO control cohort.

Observations Twenty NMO cases (females=90%; AQP4-Ab positive=60%; median age=10.5yrs) with median follow-up=6.1yrs were compared to a national cohort sample of known sequential AQP4-Ab negative first episode CNS acquired demyelination cases (n=29; females=55%; all AQP4-Ab negative; median age=13.6yrs). At presentation, 40% NMO cases had unilateral optic neuritis (ON); 20% bilateral ON; 15% transverse myelitis (TM); 15% simultaneous TM&ON; 10% Acute disseminated encephalomyelitis. At follow up, 55% had a clinical demyelinating episode involving the brain; 30% of cases had abnormal brain MRI at onset and 75% by follow up. NMO brain scan lesions compared to controls were large (>2 cm), acute lesions largely resolved on repeat imaging, and often showed T1 hypointense lesions. Mean time to relapse=0.76yrs (95% CI 0.43–1.1yrs) for AQP4-Ab positive vs 2.4yrs in AQP4-Ab negative cases (95% CI 1.1–3.6yrs). In AQP4-Ab positive cases, 10/12 had visual acuity<6/60 Snellen in ≥1 eye (0/8 AQP4-Ab negative), and 3 AQP4-Ab negative cases were wheelchair-dependent.

Conclusions In children, NMO is associated with early recurrence and visual impairment in AQP4-Ab positivity and physical disability in AP4-Ab negative relapsing cases. Distinct MRI changes appear more commonly and earlier compared to adult NMO. Early AQP4-Ab testing may allow prompt immunomodulatory treatment to minimise disability.

  • PAEDIATRIC
  • MULTIPLE SCLEROSIS
  • MRI
  • EPIDEMIOLOGY
  • NEUROIMMUNOLOGY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.